tiprankstipranks
Lixte Biotechnology Holdings (LIXT)
NASDAQ:LIXT

Lixte Biotechnology Holdings (LIXT) Stock Price & Analysis

58 Followers

LIXT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.58 - $9.50
Previous Close$3.31
Volume236.04K
Average Volume (3M)578.30K
Market Cap
$7.45M
Enterprise Value$3.24M
Total Cash (Recent Filing)$4.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.2
Beta1.02
Apr 27, 2018
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding2,249,290
10 Day Avg. Volume3,273,264
30 Day Avg. Volume578,305
Standard Deviation0.25
R-Squared0.00353
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)14.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

64.92%0.82%0.48%33.78%
64.92% Insiders
0.48% Other Institutional Investors
33.78% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

LIXT FAQ

What was Lixte Biotechnology Holdings’s price range in the past 12 months?
Lixte Biotechnology Holdings lowest stock price was $1.58 and its highest was $9.50 in the past 12 months.
    What is Lixte Biotechnology Holdings’s market cap?
    Currently, no data Available
    When is Lixte Biotechnology Holdings’s upcoming earnings report date?
    Lixte Biotechnology Holdings’s upcoming earnings report date is Apr 27, 2018 which is 2184 days ago.
      How were Lixte Biotechnology Holdings’s earnings last quarter?
      Currently, no data Available
      Is Lixte Biotechnology Holdings overvalued?
      According to Wall Street analysts Lixte Biotechnology Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Lixte Biotechnology Holdings pay dividends?
        Lixte Biotechnology Holdings does not currently pay dividends.
        What is Lixte Biotechnology Holdings’s EPS estimate?
        Lixte Biotechnology Holdings’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Lixte Biotechnology Holdings have?
        Lixte Biotechnology Holdings has 2,249,290 shares outstanding.
          What happened to Lixte Biotechnology Holdings’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Lixte Biotechnology Holdings?
          Currently, no hedge funds are holding shares in LIXT
          ---

          Lixte Biotechnology Holdings Stock Smart Score

          N/A
          Not Ranked
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Positive
          20 days / 200 days
          Momentum
          -64.02%
          12-Months-Change

          Fundamentals

          Return on Equity
          -111.07%
          Trailing 12-Months
          Asset Growth
          -22.51%
          Trailing 12-Months

          Company Description

          Lixte Biotechnology Holdings

          Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. It uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Arca Biopharma
          Aldeyra Therapeutics
          Anixa Biosciences
          Ardelyx
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis